Tobacco Treatment Comparison for Cancer Care
Summary
This pilot comparative effectiveness trial will compare two active smoking cessation treatments in terms of effectiveness, equity across patient subpopulations, and efficiency among adult patients diagnosed with cancer within the past 3 years. An enhanced treatment comprising 12 weeks of varenicline treatment and 7 smoking cessation coaching calls with a cancer focus will be compared against an active comparator modeled after standard quitline treatments (2 weeks of nicotine patch therapy with 3 phone coaching calls). Approximately 50 participants will be recruited to generate estimates of the effects, acceptability, costs, and equity of enhanced treatment (vs. standard treatment), with the primary outcome being abstinence from smoking 26 weeks after trying to quit.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2025-08-04
- Completion
- 2025-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Transdermal Nicotine Patch | Unknown | 7 mg | Other |
| Comparator | Transdermal Nicotine Patch | Unknown | 14 mg | Other |
| Comparator | Transdermal Nicotine Patch | Unknown | 21 mg | Other |
| Subject | Varenicline | Small molecule | — | Oral |